Crinetics Pharmaceuticals (CRNX) Finished Goods (2025 - 2026)
Crinetics Pharmaceuticals' quarterly Finished Goods came in at $29000.0 in Q1 2026, up 61.11% quarter-over-quarter from $18000.0 in Q4 2025.
Crinetics Pharmaceuticals has reported Finished Goods for 2 years, with the latest figure at $29000.0 in Q1 2026.
- For the quarter ending Q1 2026, Finished Goods changed N/A year-over-year to $29000.0; the trailing twelve-month figure through Mar 2026 stood at $29000.0 (changed N/A YoY), and the FY2025 full-year result was $18000.0, changed N/A from the prior year.
- Finished Goods for Q1 2026 stood at $29000.0, up from $18000.0 in the prior quarter.
- The five-year high for Finished Goods was $29000.0 in Q1 2026, with the low at $18000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 18,000.00 |